Skip to main content
. 2026 Nov 8;27(21):10001. doi: 10.3390/ijms272110001
AhR Aryl Hydrocarbon Receptor
AIEC Adherent-Invasive Escherichia coli
AMP Antimicrobial Peptide
ASCA Anti-Saccharomyces cerevisiae Antibody
BA Bile Acid
BSH Bile Salt Hydrolase
CD Crohn’s disease
CDAI Crohn’s Disease Activity Index
CDEIS Crohn’s Disease Endoscopic Index of Severity
CI Confidence interval
DCA deoxycholic acid
ESBL Extended-spectrum β-lactamase
FFAR free fatty acid receptor
FMT Fecal microbiota transplantation
FXR Farnesoid X Receptor
IBD Inflammatory Bowel Disease
IL Interleukin
IFN-γ Interferon-gamma
JAK Janus-kinase
LBP Live Biotherapeutic Product
LCA lithocholic acid
MDRO Multidrug-resistant organism
NF-κB nuclear factor kappa B
NNT Number Needed to Treat
OR Odds Ratio
rCDI Recurrent Clostridioides difficile Infection
RCT Randomized Controlled Trial
RD Risk Difference
ROS Reactive Oxygen Species
RR Risk Ratio
SCFA Short-Chain Fatty Acid
TGF-β Transforming Growth Factor Beta
TGR5 Takeda G Protein-Coupled Bile Acid Receptor 1
Th1 T Helper Type 1 Cell
Th17 T Helper Type 17 Cell
Treg Regulatory T cell
UC Ulcerative Colitis
UDCA Ursodeoxycholic Acid
ZO-1 Zonula Occludens-1